1. Introduction {#sec1}
===============

Medullary thyroid cancer (MTC) accounts for 1--3% of all cases of thyroid carcinoma and arises from parafollicular cells (C cells). About 20% of the cases are hereditary, as part of type 2 multiple endocrine neoplasia syndrome. At diagnosis, about 70--80% of the cases present with cervical lymph node (LN) metastases and 10% of cases also present with distant metastases \[[@B1]--[@B3]\].

All patients with a preoperative diagnosis of MTC should undergo neck ultrasound (US) and measurement of serum calcitonin (CT) \[[@B4]\]. Serum CT is a 32-amino acid linear polypeptide hormone, mainly produced by the C  cells, and it is regarded as a reliable MTC marker. When elevated in nonthyroidectomized patients, it should raise suspicion for its diagnosis and warrant complementary evaluation with fine-needle aspiration (FNA) cytology of suspicious thyroid nodules and cervical LN \[[@B5]\]. Thus, according to the American Thyroid Association (ATA) guidelines for the management of MTC, total thyroidectomy and dissection of cervical LN compartments, depending on serum calcitonin levels and neck US findings, is the standard treatment for patients with MTC \[[@B1]\].

There are a few other additional systemic and local therapies used to achieve tumor control, but their efficacy is limited. Therefore, complete surgical resection is of utmost importance for all MTCs and successful surgery with clear surgical margins, and removal of all LN metastases is a prerequisite for cure \[[@B1], [@B3]\].

During follow-up of MTC patients and in case of raising levels of serum CT, imaging exams should be performed in order to diagnose local recurrence, LN metastases, or distant metastases \[[@B1], [@B3]\]. LN metastases are usually diagnosed by neck ultrasound (US), as it is usually performed for the diagnosis of LN metastases of differentiated follicular thyroid carcinoma (DFTC). FNA cytology is an extremely useful method to confirm its diagnosis. However, the diagnostic accuracy of FNA cytology is lower in MTC than in DFTC (60--70% versus 90--95%) and heavily relies on the pathologists\' experience \[[@B6], [@B7]\]. Typically, aspirates are hypercellular, composed of poorly cohesive cells, which are predominantly spindle shaped. Binucleation and eccentric nuclei as well as anisonucleosis and coarse chromatin are also present, and the cytological pattern may mimic papillary, anaplastic, or follicular carcinoma \[[@B6]--[@B8]\].

Patients with DFTC also have an additional tool for the diagnosis of LN metastases: measurement of thyroglobulin (TG) in FNA washout fluid. The ATA guidelines for the management of differentiated thyroid cancer recommend using both FNA cytology and measurement of TG in the washout fluid for confirmation of malignancy in suspicious LN, with a cut-off of \<1  ng/mL for the exclusion of LN metastases \[[@B9]\]. Unlike DFTC, in which the measurement of TG is a well-established and reliable method for the diagnosis of LN metastases, in MTC, the data is sparse on the measurement of CT in FNA washout fluid (FNA-CT) of MTC LN metastases \[[@B9]\]. Few studies have been published on this subject, and they show that FNA-CT is a promising tool, as it has a higher accuracy for the diagnosis of metastatic LN than FNA cytology (60--70% versus 85--90%). However, most studies focus on this method for the diagnosis of MTC in both thyroid nodules and LN and the suggested cut-offs reflect this methodology. Besides, there are still many centers where this method is not applied and it is not recommended, yet, by the ATA guidelines for the management of MTC \[[@B1]\]. Our study aimed to further evaluate the utility of FNA-CT measurement exclusively in LN, in the diagnosis of MTC LN metastases and compare it with FNA cytology.

2. Materials and Methods {#sec2}
========================

A retrospective analysis of our institutional database identified 69 consecutive FNA cytology and CT measurement in FNA washout of LN (from 42 patients) between 2012 and 2017. Measurement of FNA-CT in the washout of LN was performed in nonthyroidectomized patients evaluated in our department for suspicious neck LN and in patients with personal history of MTC, suspicious neck LN, and progressive increase in serum CT levels. In nonthyroidectomized patients, both TG and CT were measured in the LN washout fluid to exclude LN metastases from a thyroid carcinoma, and in patients with personal history of MTC, only CT was measured as an adjunct to cytologic examination. We did not measure FNA-CT in the washout fluid of thyroid nodules.

All patients underwent a thorough neck examination, neck US, and US-guided FNA of suspicious LN for conventional cytology and measurement of FNA-CT. Neck US was performed using a Canon Xario^TM^ 100 US machine, with a 4.2--14  mHz linear electronic transducer, by an endocrinologist with at least 5 years of experience. All LNs and cervical masses were identified and localized, and their diameters were measured. Suspicious LNs were identified according to standard criteria (loss of echogenic hilum, hyperechogenicity, cystic changes, calcifications, round shape, and abnormal vascularity) and submitted to one FNA cytology under US visual guidance with a 22 or 25-gauge needle attached to a 10  mL syringe \[[@B10]\]. The endocrinologist who performed the procedure excluded specimens that might have blood in the needle. A second FNA cytology was performed in case there was a doubt if there was no LN fluid in the needle.

Cytological examination was performed by two thyroid pathologists with at least 10  years of experience, and the diagnosis of MTC was made according to standard criteria \[[@B11]\].

After smear preparation, the syringe and needle were sent to the laboratory department to be flushed with 1  mL of normal saline solution (NaCl 0.9% m/V). The needle washout was centrifuged (1500  g, 2  min), and the supernatant, which is not the cellular material, was used for analysis. The solution was processed for FNA-CT measurement with a solid-phase, enzyme-labeled, two-site chemiluminescent immunometric assay (Siemens Healthcare Diagnostics, Llanberis, Gwynedd LL55 4EL, United Kingdom, Immulite 2000XPI Calcitonin), calibrated to the World Health Organization 2nd International Reference Preparation 89/620 standard. The limits of detection and quantification were 2.0 and 5.0 pg/mL, respectively, whereas the upper reference limits were 11.5 pg/mL for females and 18.2 pg/mL for males \[[@B12]\]. Serum CT was measured using the same assay.

Histological analysis of surgical specimens was made using standard pathological techniques, including detection of CT expression by immunohistochemistry.

In this study, we included demographic (age and gender), laboratory (serum CT and FNA-CT), clinical (age and gender), and pathologic data (results from FNA cytology and histological analysis of LN) extracted from patients\' charts.

All statistical analysis was performed using SPSS Statistics 23.0 software (IBM Corp. Released 2015. IBM SPSS Statistics for Windows, Version 23.0. Armonk, NY) Parametric statistical tests (*t*-tests) were used for variables following a normal distribution. The Mann--Whitney test was used when these premises were not met. For the categorical variables, we used the chi-square test and Fisher\'s exact test. To determine the best cut-off value for washout fluid FNA-CT, we used the receiver operating characteristic (ROC) analysis.

3. Results {#sec3}
==========

This study\'s population had a mean age of 60.7 ± 15.9 years and was mainly comprised of male patients (*n* = 24 (57.1%)). Out of a total of 69 LN FNA cases, 39 (56.5%) were performed in nonthyroidectomized patients evaluated in our department for suspicious neck LN. The remaining 30 cases were performed in patients with personal history of MTC, suspicious neck LN, and progressive increase in serum CT levels. Cytologic examination detected MTC in 19 FNA (27.5%) and DFTC in 11 FNA (15.9%). Thirty-five (50.7%) FNA were diagnosed as benign and 4 (5.8%) were nondiagnostic.

Calcitonin was detectable in needle washout in 23 (33.3%) FNA. In patients with detectable levels of FNA-CT, median was 635 pg/mL (interquartile range 277--2524). These patients had a median serum CT level of 2014 (490--15111) pg/mL and a mean LN diameter of 19.7 ± 10.7 mm. These results are shown in Tables [1](#tab1){ref-type="table"} and [2](#tab2){ref-type="table"} and [Figure 1](#fig1){ref-type="fig"}.

Very high levels of FNA-CT (\>200 pg/mL) were seen in most cases (*n* = 19) and only 4 cases had needle washout CT levels below 100 pg/mL. Ten patients had two measurements of FNA-CT in the same lymph node, and 4 patients had FNA-CT measurements on different LN. Seven of the 23 detectable measurements of FNA-CT in LN washout fluid had higher levels of serum CT, and all of these cases had histologically proven MTC LN metastases ([Table 2](#tab2){ref-type="table"}).

Lymph node resection was performed in 17 patients (36 lesions, 52.1%): 9 patients (24 lesions, 34.7%) with detectable levels of FNA-CT and 8 patients (12 lesions, 17.3%) with undetectable FNA-CT. Patients with undetectable FNA-CT underwent surgery for Bethesda V on thyroid nodule cytology and LN cytology suspicious for DFTC LN metastasis. Lymph node excisional biopsy was additionally performed in 7 patients with suspicious LN on neck US but undetectable levels of FNA-CT and benign cytology. Histological examination of these LN proved them to be granulomatous disease.

Histology reported LN metastases of MTC in 8 patients (19 lesions, 52.8%) and LN metastases of DFTC in 10 patients (12 lesions, 33.3%). All but one patient with DFTC had very low levels of FNA-CT, and it was the only false-positive (FP) in our study. He had a FNA-CT level of 5.6 pg/mL, a FNA cytology suspicious for papillary thyroid carcinoma, and a serum CT of 7 pg/mL. There was only one case of positive FNA-CT (1488 pg/mL) and MTC LN metastases on cytologic examination, without histological confirmation. It was a patient with known progressive MTC with two previous lateral-cervical dissections. He was diagnosed with LN recurrence and pulmonary metastases, and it was decided not to perform an additional LN dissection, but to start systemic therapy instead. These results are shown in [Figure 2](#fig2){ref-type="fig"}.

Regarding the diagnosis of MTC LN metastases, FNA-CT showed sensitivity of 100%, specificity of 97.9%, positive predictive value (PPV) of 95.6%, and negative predictive value (NPV) of 100%. There was only one FP, as was previously mentioned. On the other hand, FNA cytology had a sensitivity of 81.8%, specificity of 97.9%, PPV of 94.7%, and NPV of 92%. This method had only one FP, which was a patient with personal history of MTC with FNA-CT of \<2 pg/mL, in which the pathology report confirmed no signs of malignancy.

FNA cytology was considered nondiagnostic in four cases (5.8%). Three of them had personal history of MTC and positive FNA-CT levels (312 pg/mL, 704 pg/mL, and 1086 pg/mL, respectively). They also had rising levels of serum CT, which increased the suspicion of metastatic disease. In these cases, high levels of FNA-CT in the washout lead to the diagnosis of LN metastases. Surgery was later performed, which confirmed the diagnosis of MTC LN metastases by histological analysis.

Combining both diagnostic methods showed the highest diagnostic power (sensitivity of 100%, specificity of 97.9%, PPV of 95.6%, and NPV of 100%). The lowest value of FNA-CT with histologically proven MTC LN metastases was 40.4 pg/mL. The optimal cut-off value of FNA-CT for determination MTC LN metastases through ROC analysis was 23.0 pg/mL (area under the curve = 99%; *P* \< 0.001), leading to a sensitivity of 100% and specificity of 100%. These results are show in [Table 3](#tab3){ref-type="table"}.

4. Discussion {#sec4}
=============

Cytologic evaluation of suspicious LN is the most used diagnostic tool for detection of MTC LN metastases \[[@B1], [@B8], [@B13]--[@B16]\]. However, its accuracy is not as high as in DFTC. In this study, we assessed the potential utility of FNA-CT alone or combined with cytology, in the diagnosis of MTC LN metastases, as it is usually performed for DFTC. Studies regarding this subject suggest that this method might be an effective auxiliary method to FNA cytology, with sensitivity ranging from 89--100%. However, in most of these studies, FNA-CT is measured in either thyroid nodules or in both thyroid nodules and suspicious neck LN. Hence, suggested cut-offs for the diagnosis of MTC are usually the same in both situations. The ideal cut-off for the diagnosis of MTC in thyroid nodules or neck LN is estimated to be 10--30 pg/mL. This is the first study that analyzed the utility of FA-CT measurement exclusively in MTC LN metastases and has the largest cohort of LN.

Our results showed that high levels of FNA-CT were present in all patients with histologically proven MTC with a sensitivity of 100% and specificity of 97.9%. The lowest value of FNA-CT in a histologically proven metastatic LN was 40.4 pg/mL, and the optimal cut-off, according to ROC analysis is 23.0 pg/mL, which is similar to other cut-offs proposed by other studies \[[@B8], [@B12], [@B13], [@B15], [@B16]\]. The only FP was a patient with a low value of FNA-CT and serum CT. This patient was submitted to surgical LN dissection and the pathology report revealed LN metastases of DFTC. In this case, it might have been a laboratory error, as the FNA-CT level fell near the functional sensitivity range.

There was a wide range of FNA-CT measurements between patients, as well as high variability between measurements in the same LN. This can be explained by the fact that each fine-needle aspiration is a different procedure in and of itself and bound to get a different amount of LN fluid, each time it is performed. The wide range of FNA-CT values in different LN might be due to the inherent differences in calcitonin secretion by different tumors. We would like to point out that, despite of the broad range in FNA-CT measurements, the diagnostic accuracy is very high and we had no false-negatives and only one false-positive.

Fine-needle aspiration cytology also showed high accuracy for the diagnosis of LN metastases and higher than previous studies (sensitivity of 81.8% and specificity of 97.9%) \[[@B12], [@B13], [@B16]\]. This can be attributed to the significant experience our pathologists have earned through the years, working in an oncology center with a large number of cases of both DFTC and MTC and to the fact that they were not blinded to the results of FNA-CT measurements.

Some studies also evaluated the potential utility of the FNA-CT/serum CT ratio for the diagnosis of MTC in thyroid nodules and LN, which could be useful in order to avoid false elevations of CT in the washout fluid if serum CT is significantly elevated. In order to avoid this potential bias, we excluded cases that might have had blood in the needle and all of them were centrifuged to ensure that only the supernatant was analyzed. We also need to keep in mind that the aspirate leftover volume is usually very small and subsequently rinsed/diluted with 1  mL of normal saline solution to overcome possible interferences of serum CT in FNA-CT measurement. Thus, we did not find the ratio FNA-CT/serum CT useful in this situation. In fact, 22 of the 23 detectable measurements were true-positives and only 7 of them had higher levels of serum CT than FNA-CT. All of these cases had histologically proven MTC LN metastases.

As with most clinical studies of thyroid cancer, this is a retrospective study and potential selection bias should be considered in the interpretation of the results. MTC is a rare entity and this study has a heterogeneous cohort. On the other hand, there is still limited evidence regarding CT measurement in FNA washout fluid. Therefore, in this context, we believe that it is important to evaluate and describe the results from clinical practice.

5. Conclusion {#sec5}
=============

This is the largest study regarding the diagnostic utility of FNA-CT for detection of MTC exclusively in LN. It further supports the value of FNA-CT as a reliable and inexpensive diagnostic tool, along with FNA cytology, that should be included in the clinical workup of neck adenopathies in patients with thyroid nodules or medical history of MTC. However, there is still need for further studies in order to assess the actual relevance of this technique in the management of MTC and validate the optimal cut-off value for the diagnosis of LN metastases.
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###### 

Patients characteristics according to FNA-CT measurement.

                               FNA-CT measurements *N* = 69 (42 patients)   *P*                      
  ---------------------------- -------------------------------------------- -------------- --------- -----
  Gender                       Female                                       4              15        NSS
  Male                         6                                            17                       
                                                                                                     
  Age (years)                  63.2 ± 16.7                                  57.9 ± 14.2    NSS       
  Personal history of MTC      7                                            6              NSS       
  FNA-CT levels (pg/mL)^*∗*^   2014 (490 -- 15111)                          \<2 (0)        \<0.001   
  Serum CT (pg/mL)^*∗*^        635 (277 -- 2524)                            1 (1 -- 277)   0.016     
  LN diameter (mm)             19.7 ± 10.7                                  16.2 ± 6.1     0.014     

FNA-CT levels and serum CT levels expressed as median (interquartile range); age and LN diameter expressed as mean ± standard deviation; NSS = no statistical significance.

###### 

Patients with detectable levels of FNA-CT in LN washout fluid (available as a supplementary file).

                Personal history      LN (size, mm)       FNAC                FNA-CT (pg/mL)      Serum CT (pg/mL)    Histology
  ------------- --------------------- ------------------- ------------------- ------------------- ------------------- --------------------
  Patient 1     MTC                   LN1 (18)            MTC LN metastasis   200000              86.9                MTC LN metastasis
  Patient 2     MTC                   LN 1 (17.4)         Nondiagnostic       704                 932                 MTC LN metastasis
  Patient 3     MTC                   LN 1 (15.5)         Nondiagnostic       1086                533                 MTC LN metastasis
  Patient 4     MTC                   LN1 (15)            Nondiagnostic       312                 9704                MTC LN metastasis
  Patient 5     MTC                   LN1 (16)            MTC LN metastasis   85621               635                 MTC LN metastasis
  Patient 6     MTC                   LN 1 (25)           Benign              \<2                 794                 ---
  \<2                                                                                                                 
  LN 2 (40)     MTC LN metastasis     11065               3796                MTC LN metastasis                       
  40226                                                                                                               
  LN3 (15)      MTC LN metastasis     4913                121                 MTC LN metastasis                       
  LN 4 (12)     Benign                \<2                 340                 ---                                     
  \<2                                                                                                                 
  Patient 7     Nonthyroidectomized   LN 1 (45)           MTC LN metastasis   15111               1871                MTC LN metastasis
  MTC           LN 2 (14)             MTC LN metastasis   6779                1224                MTC LN metastasis   
  60.2          1224                                                                                                  
  Patient 8     MTC                   LN 1 (13.2)         MTC LN metastasis   117                 277                 MTC LN metastasis
  2014                                                                                                                
  LN 2 (18.8)   MTC LN metastasis     4653                MTC LN metastasis                                           
  LN 3 (12)     Benign                \<2                 545                 ---                                     
  \<2                                                                                                                 
  LN 4 (14)     Benign                \<2                 ---                                                         
  LN 5 (18)     MTC LN metastasis     40.4                598                 MTC LN metastasis                       
  490                                                                                                                 
  LN 6 (13)     MTC LN metastasis     838                 515                 MTC LN metastasis                       
  1686                                                                                                                
  Patient 9     Nonthyroidectomized   LN 1 (25.5)         DTFC                5.6                 7                   DFTC LN metastasis
  Patient 10    Nonthyroidectomized   LN 1 (25)           MTC LN metastasis   7364                5007                MTC LN metastasis
  66104                                                                                                               
  MTC           LN 2 (28.4)           MTC LN metastasis   200000              1355                MTC LN metastasis   
  LN 3 (27)     MTC LN metastasis     1488                2524                ^*∗*^                                   

^*∗*^One patient with a detectable FNA-CT (1488 pg/mL) and MTC LN metastases on cytologic examination did not undergo surgery and started systemic therapy.

###### 

Diagnostic accuracy of FNA cytology and FNA-CT.

                          MTC          Non-MTC      Nondiagnostic   Sensitivity (%)   Specificity (%)   PPV (%)   NPV (%)
  ----------------------- ------------ ------------ --------------- ----------------- ----------------- --------- ---------
  FNA cytology            19 (27.5%)   46 (66.6%)   4 (5.8%)        81.8              97.9              94.7      92.0
  FNA-CT                  23 (33.3%)   46 (66.6%)   ---             100               97.9              95.6      100
  FNA cytology + FNA-CT   23 (33.3%)   46 (66.6%)   ---             100               97.9              95.6      100
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